Moss Genomics Announces Closing of Financing Round
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") announces that, effective as of November 11, 2025, it has closed a non-brokered private placement of 555,555 common shares at $0.18 per share for gross proceeds of $100,000. No finder's fees were paid. Net proceeds will be used for general working capital. In addition, effective as of November 11, 2025, Moss issued an aggregate
2025-11-12 7:01 PM EST | Moss Genomics Inc.
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, 2025 (the company's fiscal Q2 2026). All dollar amounts in this press release are in United States dollars unless specified otherwise. Key business update Medexus is currently focused on delivering strong p
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-12 6:06 PM EST | Medexus Pharmaceuticals Inc.
Restart Life Sciences Announces Private Placement Financing
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce a non-brokered private placement of up to 10,000,000 units in the capital of the Company (each, a "Unit") at a price of CAD $0.10 per Unit for aggregate gross proceeds of up to CAD $1,000,000 (the "Offering"). Each Unit purchased will include one common share and one transferable common share p
Technology, Biotechnology, Health
2025-11-12 4:22 PM EST | Restart Life Sciences Corp.
BioHarvest Sciences to Attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the Craig-Hallum 16th Annual Alpha Select Conference taking place on Tuesday, November 18th, 2025 in New York, NY.
Biotechnology, Pharmaceuticals, Health
2025-11-12 8:42 AM EST | BioHarvest Sciences Inc.
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to support the Canadian Cancer Society's national plan to reduce lung cancer mortality in Canada by 30% over the next decade. The early detection activities and goals outlined in the 2026-2035 Pan-Canadia
Technology, Biotechnology, Healthcare and Hospitals
2025-11-12 8:30 AM EST | BioMark Diagnostics, Inc.
Izotropic Launches Podcast Episode #2: AI and the Future of Breast Imaging: How Izotropic is Leading the Innovation
Sacramento, California--(Newsfile Corp. - November 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the release of the second episode in its podcast series:
2025-11-12 8:00 AM EST | Izotropic Corporation
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - November 10, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 35,697 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees. The DSUs will all vest on October 31, 2026. Vested DSUs shall be settled upon the directors' separation from service fro
2025-11-10 5:15 PM EST | Marvel Biosciences Corp.
BioHarvest Sciences Announces Closing of $19.9 Million Upsized Public Offering of Common Stock and Exercise of Underwriter's Option to Purchase Additional Shares
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 10, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the closing of its previously announced underwritten public offering of 2,846,854 shares of common stock, no par value, and at a public offering price of $7.00 per share, which includes 361,854 shares issued upon the exercise by the
Biotechnology, Pharmaceuticals, Health
2025-11-10 4:18 PM EST | BioHarvest Sciences Inc.
Envoy Medical Reports Third Quarter 2025 Financial and Operational Results
White Bear Lake, Minnesota--(Newsfile Corp. - November 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced its corporate and financial results for the third quarter ended September 30, 2025, as well as other subsequent events. Corporate Highlights for Third Quarter 2025:
Biotechnology, Healthcare and Hospitals
2025-11-10 8:00 AM EST | Envoy Medical, Inc.
Theralase(R) Releases 3Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited condensed consolidated interim 3Q2025 financial statements ("Financial Statements"). Theralase® will be host
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-11-10 7:00 AM EST | Theralase Technologies Inc.
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its ongoing Phase 1b clinical trial at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in National Harbor, Ma
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 10:30 AM EST | Phio Pharmaceuticals Corp.
Impact Fusion International Inc. is Pleased to Announce That the " Florida Statewide Organization (FSO) of Omega Psi Phi Fraternity, Inc.," Has Created an Agricultural Committee to Test Impact Fusion's Proprietary Technology Against Citrus Greening, Citrus Canker, Increase Fruit Tree Yield, Increase Chicken Egg Production, and Producing Quality Beef Without New World Screwworms Infections With a Targeted Effort to Decrease Food Insecurity
Napoleonville, Louisiana--(Newsfile Corp. - November 7, 2025) - Impact Fusion (OTCID: IFUS). The Florida Statewide Organization of Omega Psi Phi Fraternity, Inc., the esteemed historically Black Greek-letter organization, proudly announced the formation of its Agricultural Committee. This initiative is designed to harness the innovative Supreme AG™,SGP+™, SGP+P™, and Intact Digest™ technologies developed by Impact Fusion International. This technology is designed to
2025-11-07 9:18 AM EST | Impact Fusion International Inc.
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that its INTASYL compound PH-762 is the winner of the 2025 Immunomodulatory Solution of the Year award. This is the fifth annual BioTech Breakthrough Awards program conducted by
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 7:45 AM EST | Phio Pharmaceuticals Corp.
BioHarvest Sciences Announces Pricing of $17.4 Million Upsized Public Offering of Common Stock
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the pricing of an underwritten public offering of 2,485,000 shares of common stock, no par value, and at a public offering price of $7.00 per share. BioHarvest expects the gross proceeds from this offering to be approximately $17.4 m
Biotechnology, Pharmaceuticals, Health
2025-11-07 7:30 AM EST | BioHarvest Sciences Inc.
Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
Encinitas, California--(Newsfile Corp. - November 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2025 financial results and provided an update on its pipeline of small molecules for the treatment of retinal diseases. Key third quarter and 2025 year-to-date corporate highlights include: Continued recruitment and patient dosing in KLARITY, an open-label Phase 2 clinical trial evaluating KIO-104 for the treatmen
Biotechnology, Pharmaceuticals
2025-11-07 6:00 AM EST | Kiora Pharmaceuticals, Inc.
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its first quarter of fiscal year 2026, which ended September 30, 2025. The Company's full financial statements and related MD&A for the first quarter
Biotechnology, Pharmaceuticals
2025-11-06 4:51 PM EST | InMed Pharmaceuticals
BioHarvest Announces Proposed Public Offering of Common Stock
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 6, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, BioHarvest also expects to grant the underwriter a 30-day option to purchase up to an additional
Biotechnology, Pharmaceuticals, Health
2025-11-06 4:37 PM EST | BioHarvest Sciences Inc.
Nextleaf Announces Launch of New Recreational Cannabis Brand
Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to announce the national launch of its new recreational brand, Yard. Yard is designed for adult-use consumers seeking bold recreational cannabis experiences through high-potency extracts, premium hardware, and flavour-forward formul
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2025-11-06 9:29 AM EST | Nextleaf Solutions Ltd.
Neural's Portfolio Company Hanf.com Expands Retail Footprint to Northern Germany with Two New Stores in Bielefeld and Herford
Toronto, Ontario--(Newsfile Corp. - November 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, in which it owns 30.75% int
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-11-06 8:46 AM EST | Neural Therapeutics Inc.
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce the successful presentation of new data on its proprietary Accum® platform at the 16th World ADC Conference in San Diego, USA (November 4-5, 2025). The presentation generated exceptional interest from both the scientific a
Biotechnology, Pharmaceuticals, Health
2025-11-06 3:15 AM EST | Defence Therapeutics Inc.